News
Lowey Dannenberg and Co-Counsel File Class Action on Behalf of End-Payors for Immunosuppressive Drug Stelara (Ustekinumab)
On December 7, 2023, Lowey Dannenberg, P.C. and its co-counsel, representing named Plaintiff CareFirst BlueCross BlueShield,filed suit against Stelara manufacturer Johnson & Johnson (“J&J”) in the U.S. District Court for the Eastern District of Virginia. The...
Seven Lowey Dannenberg Attorneys Named as 2023 New York Metro Super Lawyers and Rising Stars
Seven Lowey Dannenberg Attorneys Named as 2023 New York Metro Super Lawyers and Rising Stars
Lowey Dannenberg Appointed Interim Co-Lead Counsel in GoodRx Privacy Litigation
On July 7, 2023, Judge Araceli Martínez-Olguín appointed Lowey Dannenberg, P.C. as Interim Co-Lead Counsel representing a proposed class of plaintiffs in the consolidated action: Doe v. GoodRx Holdings, Inc., No. 3:23-cv-00501 (N.D. Cal.). GoodRx Holdings, Inc....
Lowey Appointed Interim Lead Counsel for End-Payor Plaintiffs in Amitiza Antitrust Litigation
On June 27, 2023, Judge Richard G. Stearns of the U.S. District Court for the District of Massachusetts appointed Lowey Dannenberg, P.C. as interim lead counsel for end-payor plaintiffs in Premera Blue Cross v. Takeda Pharmaceutical Company Limited et al., No....